The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.本揭露針對修飾結合分子以最小化已存在的結合交互作用,包括將結合分子經工程以最小化或減輕由藥物非特異性結合交互作用引起之樣本基質中的背景反應性。